Furthermore, topical imiquimod (Aldara), FDA-approved in 2004 for primary superficial BCC treatment, inhibits the Shh pathway by inducing protein kinase A-mediated GLI phosphorylation [490]. Here, GLI1 is linked to skin basal cell carcinoma.